Why the study?
Does ICRF-159 prevent doxorubicin-induced cardiotoxicity, nephrotoxicity, and neurotoxicity in rats?
Does ICRF-159 prevent doxorubicin-induced cardiotoxicity, nephrotoxicity, and neurotoxicity in rats?
In a rat model, ICRF-159 pretreatment attenuates doxorubicin-induced cardiotoxicity, nephrotoxicity, and neurotoxicity, though it exacerbates bone marrow depression.
ICRF-159 attenuates doxorubicin toxicities in rats except marrow suppression; leaves open clinical translation and net benefit.
Cardiotoxicity of doxorubicin, 2 mg/kg i.p. twice weekly in rats, was assessed by serial electrocardiography and electron microscopy. The toxic effects were markedly inhibited by ICRF-159, 50 mg/kg p.o. given 1 h before doxorubicin. The development of nephropathy characterized by proteinuria, hyperlipidemia and glomerular and tubular changes was significantly retarded, and the degenerative changes of peripheral nerves were markedly reduced. On the other hand, ICRF-159 enhanced the depressant effects of doxorubicin on bone marrow function. Doxorubicin reduced body weight gain, caused ascites, decrease in heart and thymus weight, and increase in liver and kidney weight. These changes were also inhibited or attenuated by ICRF-159 pretreatment.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: